정신분열증 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(-2031년) - 제품 유형별, 유통 채널별, 지역별

Schizophrenia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

US $ 4,995 ￦ 6,942,000

Unprintable PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 텍스트의 Copy&Paste도 불가능합니다.

US $ 8,495 ￦ 11,806,000

Unprintable PDF & Excel (Multi User License upto 5 users)

PDF 및 Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트는 Copy & Paste 가능하지만, 인쇄는 불가능합니다.

US $ 10,600 ￦ 14,731,000

Printable PDF & Excel (Enterprise License above 5 users)

PDF 및 Excel 보고서를 동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용자수는 5명 이상이며 제한은 없습니다. Copy & Paste 및 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

정신분열증은 현실에 대한 비정상적인 해석이 특징이며 환각과 망상을 포함한 다양한 행동 변화를 일으킵니다. 정신분열증의 치료는 지속적으로 이루어지며, 약물치료는 뇌의 도파민 수치를 조절하여 환자의 행동을 조절하는 데 매우 중요한 역할을 합니다.

항정신병약물, 특히 2세대 항정신병약물은 1세대 항정신병약물에 비해 부작용이 적기 때문에 일반적으로 처방되고 있습니다. 약물치료와 더불어 개별치료, 사회기술치료 등의 치료도 병행하여 정신분열증 환자의 삶의 질을 향상시키고 있습니다.

세계보건기구(WHO)에 따르면, 전 세계적으로 약 5,000만 명이 정신분열증을 앓고 있습니다. 유병률은 감소하고 있지만, 이 질환의 진단율과 처방률은 계속 상승하고 있어 정신분열증 치료제가 크게 성장할 것으로 예상됩니다.

진단율의 증가는 치료를 찾는 환자 수가 증가함에 따라 1970년 정신분열증에 대한 최초의 비정형 항정신병약물이 도입된 이후 비정형 항정신병약물과 관련된 부작용이 감소함에 따라 치료 추구가 눈에 띄게 증가했습니다.

정신분열증 치료제 시장의 주요 기업들은 기회를 포착하기 위해 상업화 제휴 및 연구 제휴를 적극적으로 추진하고 있습니다. 공동연구와 제휴는 M&A보다 더 효과적이며 즉각적으로 긍정적인 영향을 미치는 것으로 입증되었습니다. 정신분열증 치료제 제조업체들도 신흥 시장을 수익 창출의 길로 모색하고 있습니다.

이 보고서는 세계 정신분열증 치료 시장에 대해 조사했으며, 시장 개요와 함께 제품 유형별, 유통 채널별, 지역별 동향, 시장 진입 기업의 경쟁 동향 등을 정리하여 전해드립니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 정의와 세분화
• 시장 역학
• 밸류체인 분석
• Porter's Five Forces 분석
• COVID-19의 영향 분석
• 우크라이나와 러시아 분쟁의 영향
• 경제 개요
• PESTLE 분석

제3장 세계의 정신분열증 치료 시장 전망, 2018-2031년

• 세계의 정신분열증 치료 시장 전망, 제품 유형별, 금액(100만 달러), 2018-2031년
• 세계의 정신분열증 치료 시장 전망, 유통 채널별, 금액(100만 달러), 2018-2031년
• 세계의 정신분열증 치료 시장 전망, 지역별, 금액(100만 달러), 2018-2031년

제4장 북미의 정신분열증 치료 시장 전망, 2018-2031년

제5장 유럽의 정신분열증 치료 시장 전망, 2018-2031년

제6장 아시아태평양의 정신분열증 치료 시장 전망, 2018-2031년

제7장 라틴아메리카의 정신분열증 치료 시장 전망, 2018-2031년

제8장 중동 및 아프리카의 정신분열증 치료 시장 전망, 2018-2031년

제9장 경쟁 상황

• 제조업체와 유통 채널별 히트맵
• 기업의 시장 점유율 분석, 2023년
• 경쟁력 대시보드
• 기업 개요
  • Johnson & Johnson Services, Inc.
  • Bristol-Myers Squibb Company
  • Otsuka Holdings Co., Ltd
  • AstraZeneca
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Eli Lilly and Company
  • Alkermes
  • Vanda Pharmaceuticals
  • ALLERGAN
  • Pfizer Inc.

제10장 부록

ksm

영문 목차

영문목차

Schizophrenia, a chronic disorder that profoundly impacts individuals' lives, is characterized by an abnormal interpretation of reality and leads to various behavioral changes, including hallucinations and delusions. Schizophrenia treatment is an ongoing journey, with medications playing a pivotal role in controlling patients' behavior by regulating dopamine levels in the brain.

Advancements in Treatment

Antipsychotic medications, particularly second-generation antipsychotics, are commonly prescribed due to their reduced side effects compared to first-generation counterparts. In addition to medication, schizophrenia is also addressed through therapies such as individual therapy and social skill therapy, enhancing the quality of life for individuals living with schizophrenia.

Global Market Insights

A comprehensive research report on the global schizophrenia treatment market explores various therapies and their market scenarios across different regions. The report delves into trends, drivers, challenges, and opportunities shaping the landscape. According to the research, the global schizophrenia treatment market is poised for robust expansion in the coming years.

The Burden of Schizophrenia

According to the World Health Organization, approximately 50 million people worldwide are affected by schizophrenia. Despite a declining prevalence rate, the diagnosis and prescription rates for this disorder continue to rise, creating substantial growth prospects for schizophrenia treatment.

The increasing rate of diagnosis can be attributed to a growing number of patients seeking treatment. Since the introduction of the first atypical antipsychotic treatment for schizophrenia in 1970, the pursuit of treatment has significantly increased, thanks to the reduced side effects associated with atypical psychotic medications.

Collaborative Efforts Drive Market Growth

Key players in the schizophrenia treatment market are actively forging commercialization and research alliances to seize opportunities. Collaborations and partnerships have proven to be more effective than mergers and acquisitions, yielding immediate positive impacts. Manufacturers of schizophrenia medications are also exploring emerging markets as avenues for revenue generation.

Atypical Antipsychotics Take the Lead

Among the various medications available for schizophrenia, atypical antipsychotic treatment, a second-generation medication, stands out for its effectiveness and fewer side effects. The atypical antipsychotics segment is projected to experience high growth during the forecast period.

Miscellaneous antipsychotic agents, including lithium, pimozide, molindone, haloperidol, and loxapine, are also gaining traction. Physicians often opt for haloperidol and lithium due to their effectiveness and competitive pricing. The miscellaneous antipsychotic agents segment is expected to expand at a value CAGR of 6.1% throughout the assessment period.

As the global schizophrenia treatment market continues to evolve, it holds the promise of transforming the lives of individuals affected by this challenging disorder. The focus on innovative treatments and collaborative efforts reflects the commitment of stakeholders to improve the well-being and outlook for those living with schizophrenia.

Schizophrenia Treatment Market Segmentation:

By Product Type

• Atypical Antipsychotics
• Phenothiazine Antipsychotics
• Thioxanthenes
• Miscellaneous Antipsychotic Agents

By Distribution Channel

• Hospital Pharmacies
• Drug Stores
• Retail Pharmacies
• E-Commerce

By Region

• North America
• Latin America
• Western Europe
• Eastern Europe
• Asia Pacific Excluding Japan (APEJ)
• Japan
• Middle East and Africa (MEA)

Table of Contents

1. Executive Summary

• 1.1. Global Schizophrenia Treatment Market Snapshot
• 1.2. Future Projections
• 1.3. Key Market Trends
• 1.4. Regional Snapshot, by Value, 2023
• 1.5. Analyst Recommendations

2. Market Overview

• 2.1. Market Definitions and Segmentations
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Market Opportunities
• 2.3. Value Chain Analysis
• 2.4. Porter's Five Forces Analysis
• 2.5. COVID-19 Impact Analysis
  • 2.5.1. Supply
  • 2.5.2. Demand
• 2.6. Impact of Ukraine-Russia Conflict
• 2.7. Economic Overview
  • 2.7.1. World Economic Projections
• 2.8. PESTLE Analysis

3. Global Schizophrenia Treatment Market Outlook, 2018 - 2031

• 3.1. Global Schizophrenia Treatment Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
  • 3.1.1. Key Highlights
    • 3.1.1.1. Atypical Antipsychotics
    • 3.1.1.2. Phenothiazine Antipsychotics
    • 3.1.1.3. Thioxanthenes
    • 3.1.1.4. Miscellaneous Antipsychotic Agents
• 3.2. Global Schizophrenia Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
  • 3.2.1. Key Highlights
    • 3.2.1.1. Hospital Pharmacies
    • 3.2.1.2. Drug Stores
    • 3.2.1.3. Retail Pharmacies
    • 3.2.1.4. E-Commerce
• 3.3. Global Schizophrenia Treatment Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
  • 3.3.1. Key Highlights
    • 3.3.1.1. North America
    • 3.3.1.2. Europe
    • 3.3.1.3. Asia Pacific
    • 3.3.1.4. Latin America
    • 3.3.1.5. Middle East & Africa

4. North America Schizophrenia Treatment Market Outlook, 2018 - 2031

• 4.1. North America Schizophrenia Treatment Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
  • 4.1.1. Key Highlights
    • 4.1.1.1. Atypical Antipsychotics
    • 4.1.1.2. Phenothiazine Antipsychotics
    • 4.1.1.3. Thioxanthenes
    • 4.1.1.4. Miscellaneous Antipsychotic Agents
• 4.2. North America Schizophrenia Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
  • 4.2.1. Key Highlights
    • 4.2.1.1. Hospital Pharmacies
    • 4.2.1.2. Drug Stores
    • 4.2.1.3. Retail Pharmacies
    • 4.2.1.4. E-Commerce
  • 4.2.2. BPS Analysis/Market Attractiveness Analysis
• 4.3. North America Schizophrenia Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
  • 4.3.1. Key Highlights
    • 4.3.1.1. U.S. Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
    • 4.3.1.2. U.S. Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 4.3.1.3. Canada Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
    • 4.3.1.4. Canada Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
  • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Schizophrenia Treatment Market Outlook, 2018 - 2031

• 5.1. Europe Schizophrenia Treatment Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
  • 5.1.1. Key Highlights
    • 5.1.1.1. Atypical Antipsychotics
    • 5.1.1.2. Phenothiazine Antipsychotics
    • 5.1.1.3. Thioxanthenes
    • 5.1.1.4. Miscellaneous Antipsychotic Agents
• 5.2. Europe Schizophrenia Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
  • 5.2.1. Key Highlights
    • 5.2.1.1. Hospital Pharmacies
    • 5.2.1.2. Drug Stores
    • 5.2.1.3. Retail Pharmacies
    • 5.2.1.4. E-Commerce
  • 5.2.2. BPS Analysis/Market Attractiveness Analysis
• 5.3. Europe Schizophrenia Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
  • 5.3.1. Key Highlights
    • 5.3.1.1. Germany Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
    • 5.3.1.2. Germany Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.3.1.3. U.K. Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
    • 5.3.1.4. U.K. Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.3.1.5. France Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
    • 5.3.1.6. France Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.3.1.7. Italy Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
    • 5.3.1.8. Italy Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.3.1.9. Turkey Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
    • 5.3.1.10. Turkey Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.3.1.11. Russia Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
    • 5.3.1.12. Russia Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.3.1.13. Rest of Europe Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
    • 5.3.1.14. Rest of Europe Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
  • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Schizophrenia Treatment Market Outlook, 2018 - 2031

• 6.1. Asia Pacific Schizophrenia Treatment Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
  • 6.1.1. Key Highlights
    • 6.1.1.1. Atypical Antipsychotics
    • 6.1.1.2. Phenothiazine Antipsychotics
    • 6.1.1.3. Thioxanthenes
    • 6.1.1.4. Miscellaneous Antipsychotic Agents
• 6.2. Asia Pacific Schizophrenia Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
  • 6.2.1. Key Highlights
    • 6.2.1.1. Hospital Pharmacies
    • 6.2.1.2. Drug Stores
    • 6.2.1.3. Retail Pharmacies
    • 6.2.1.4. E-Commerce
  • 6.2.2. BPS Analysis/Market Attractiveness Analysis
• 6.3. Asia Pacific Schizophrenia Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
  • 6.3.1. Key Highlights
    • 6.3.1.1. China Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
    • 6.3.1.2. China Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.3.1.3. Japan Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
    • 6.3.1.4. Japan Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.3.1.5. South Korea Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
    • 6.3.1.6. South Korea Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.3.1.7. India Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
    • 6.3.1.8. India Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.3.1.9. Southeast Asia Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
    • 6.3.1.10. Southeast Asia Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.3.1.11. Rest of Asia Pacific Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
    • 6.3.1.12. Rest of Asia Pacific Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
  • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Schizophrenia Treatment Market Outlook, 2018 - 2031

• 7.1. Latin America Schizophrenia Treatment Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
  • 7.1.1. Key Highlights
    • 7.1.1.1. Atypical Antipsychotics
    • 7.1.1.2. Phenothiazine Antipsychotics
    • 7.1.1.3. Thioxanthenes
    • 7.1.1.4. Miscellaneous Antipsychotic Agents
• 7.2. Latin America Schizophrenia Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
  • 7.2.1. Key Highlights
    • 7.2.1.1. Hospital Pharmacies
    • 7.2.1.2. Drug Stores
    • 7.2.1.3. Retail Pharmacies
    • 7.2.1.4. E-Commerce
  • 7.2.2. BPS Analysis/Market Attractiveness Analysis
• 7.3. Latin America Schizophrenia Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
  • 7.3.1. Key Highlights
    • 7.3.1.1. Brazil Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
    • 7.3.1.2. Brazil Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 7.3.1.3. Mexico Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
    • 7.3.1.4. Mexico Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 7.3.1.5. Argentina Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
    • 7.3.1.6. Argentina Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 7.3.1.7. Rest of Latin America Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
    • 7.3.1.8. Rest of Latin America Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
  • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Schizophrenia Treatment Market Outlook, 2018 - 2031

• 8.1. Middle East & Africa Schizophrenia Treatment Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
  • 8.1.1. Key Highlights
    • 8.1.1.1. Atypical Antipsychotics
    • 8.1.1.2. Phenothiazine Antipsychotics
    • 8.1.1.3. Thioxanthenes
    • 8.1.1.4. Miscellaneous Antipsychotic Agents
• 8.2. Middle East & Africa Schizophrenia Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
  • 8.2.1. Key Highlights
    • 8.2.1.1. Hospital Pharmacies
    • 8.2.1.2. Drug Stores
    • 8.2.1.3. Retail Pharmacies
    • 8.2.1.4. E-Commerce
• 8.3. Middle East & Africa Schizophrenia Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
  • 8.3.1. Key Highlights
    • 8.3.1.1. GCC Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
    • 8.3.1.2. GCC Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.3.1.3. South Africa Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
    • 8.3.1.4. South Africa Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.3.1.5. Egypt Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
    • 8.3.1.6. Egypt Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.3.1.7. Nigeria Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
    • 8.3.1.8. Nigeria Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.3.1.9. Rest of Middle East & Africa Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
    • 8.3.1.10. Rest of Middle East & Africa Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
  • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

• 9.1. Manufacturer vs by Distribution Channel Heatmap
• 9.2. Company Market Share Analysis, 2023
• 9.3. Competitive Dashboard
• 9.4. Company Profiles
  • 9.4.1. Johnson & Johnson Services, Inc.
    • 9.4.1.1. Company Overview
    • 9.4.1.2. Product Portfolio
    • 9.4.1.3. Financial Overview
    • 9.4.1.4. Business Strategies and Development
  • 9.4.2. Bristol-Myers Squibb Company
    • 9.4.2.1. Company Overview
    • 9.4.2.2. Product Portfolio
    • 9.4.2.3. Financial Overview
    • 9.4.2.4. Business Strategies and Development
  • 9.4.3. Otsuka Holdings Co., Ltd
    • 9.4.3.1. Company Overview
    • 9.4.3.2. Product Portfolio
    • 9.4.3.3. Financial Overview
    • 9.4.3.4. Business Strategies and Development
  • 9.4.4. AstraZeneca
    • 9.4.4.1. Company Overview
    • 9.4.4.2. Product Portfolio
    • 9.4.4.3. Financial Overview
    • 9.4.4.4. Business Strategies and Development
  • 9.4.5. Sumitomo Dainippon Pharma Co., Ltd.
    • 9.4.5.1. Company Overview
    • 9.4.5.2. Product Portfolio
    • 9.4.5.3. Financial Overview
    • 9.4.5.4. Business Strategies and Development
  • 9.4.6. Eli Lilly and Company
    • 9.4.6.1. Company Overview
    • 9.4.6.2. Product Portfolio
    • 9.4.6.3. Financial Overview
    • 9.4.6.4. Business Strategies and Development
  • 9.4.7. Alkermes
    • 9.4.7.1. Company Overview
    • 9.4.7.2. Product Portfolio
    • 9.4.7.3. Financial Overview
    • 9.4.7.4. Business Strategies and Development
  • 9.4.8. Vanda Pharmaceuticals
    • 9.4.8.1. Company Overview
    • 9.4.8.2. Product Portfolio
    • 9.4.8.3. Financial Overview
    • 9.4.8.4. Business Strategies and Development
  • 9.4.9. ALLERGAN
    • 9.4.9.1. Company Overview
    • 9.4.9.2. Product Portfolio
    • 9.4.9.3. Financial Overview
    • 9.4.9.4. Business Strategies and Development
  • 9.4.10. Pfizer Inc.
    • 9.4.10.1. Company Overview
    • 9.4.10.2. Product Portfolio
    • 9.4.10.3. Financial Overview
    • 9.4.10.4. Business Strategies and Development

10. Appendix

• 10.1. Research Methodology
• 10.2. Report Assumptions
• 10.3. Acronyms and Abbreviations

관련자료